MedTrace Logo

Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

NCT04074837 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2023-02-17

No results posted yet for this study

Summary

The purpose of this study is to examine the safety, tolerability and pharmacokinetics of single and multiple doses of NNI-362 in healthy aged population.

Conditions

  • Alzheimer Disease

Interventions

DRUG

NNI-362

NNI-362 small molecule in liquid suspension.

DRUG

Placebo

Placebo liquid suspension

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Neuronascent, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2021-07-31
Completion
2021-08-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04074837 on ClinicalTrials.gov